BIOVEGEN participates in the meeting of the R&D&i Commission of the CEOE

On April 24, BIOVEGEN participated in the meeting of the CEOE R&D&i Commission which, due to current circumstances, was held in virtual format. This Commission works with the objective of improving the competitiveness of the Spanish industrial sector and promoting increased investment in R&D&I activities. Specifically, in this session the draft of the document was presented “No company should stop its R&D&i activity”.

This document is placed in the scenario just when the health crisis is ending and, consequently, we are in a position to formulate the precise policies for the very critical next 24 months; extraordinary period of recovery that pursues two primary objectives: to accelerate the recovery of the normal rhythm of economic cycles and to ensure that no company falls into the temptation of not prioritizing its commitments to R&D&I while encouraging new entities to join in that creative activity. Therefore, the structure of the document consists of a set of proposals, formulated in a very concise way, so that the Government of Spain can take them into account in order to formulate an extraordinary period of recovery of business activity and maintain the business fabric and generate new products and processes that will serve the following decades.